About Superluminal Medicines
Superluminal Medicines is a private company based in Boston, Massachusetts, incorporated in 2023 in Delaware. It has reported $116,201,563 raised in four offerings on Form D since August 2023. Its chief executive is Cony D'cruz.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Sep 3, 2026 | $65,480,796fully sold | 16 | $4.0M | EquityRule 506(b) | Form D ↗ |
| Aug 14, 2025 | Aug 26, 2025 | $5,000,000fully sold | 1 | $5.0M | Debt, Convertible promissory note and the securities issuable upon conversion thereof.Rule 506(b) | Form D ↗ |
| Aug 21, 2024 | Sep 4, 2024 | $20,041,660of $119.9M target | 12 | $1.6M | EquityRule 506(b) | Form D ↗ |
| Mar 3, 2023 | Aug 28, 2023 | $25,679,107fully sold | 7 | $3.6M | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $116,201,563 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Superluminal Medicines's Form D filed Sep 3, 2026.
HP
Harsha Paladugu
Director
DX
Diamantis Xylas
Director
DM
Dylan Morris
Managing Director at Insight Partners
Also a board member at Averna Therapeutics and a director at Gameto and ImmuneBridge.
CC
NS
Nandita Shangari
Director
Earlier filings also listed Andrew Levin (director, last listed Aug 2025), Catherine Riesen (executive officer, last listed Sep 2024) and Craig Randall (executive officer, last listed Aug 2023).